Source: ERS Course 2020 - Pulmonary hypertension and pulmonary vascular disease
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Robert Naeije (BRUSSELS, Belgium). Clinical trials in pulmonary arterial hypertension: what they tell us. ERS Course 2020 - Pulmonary hypertension and pulmonary vascular disease

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary arterial hypertension patients underrepresented in clinical trials – Are they different? Source: International Congress 2016 – Pulmonary hypertension: the clinic II Year: 2016 Do we need controlled clinical trials in pulmonary arterial hypertension? Source: Eur Respir J 2001; 17: 1-3 Year: 2001 End-points and clinical trial design in pulmonary arterial hypertension: have we made progress? Source: Eur Respir J 2009; 34: 231-242 Year: 2009 Interpreting risk reduction in clinical trials for pulmonary arterial hypertension Source: Eur Respir Rev, 27 (148) 180020; 10.1183/16000617.0020-2018 Year: 2018 Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed Source: Eur Respir J 2010; 36: 986-990 Year: 2010 Acute vasodilator testing in idiopathic pulmonary arterial hypertension: must we take NO for the answer? Source: Eur Respir J 2009; 33: 1247-1249 Year: 2009 Pulmonary hypertension: what can we learn from studies? Source: International Congress 2015 – Practising personalised medicine: why, when, and how? Year: 2015 Goal-oriented therapy in paediatric pulmonary arterial hypertension: are we ready? Source: Eur Respir J 2014; 44: 1404-1407 Year: 2014 The effects of beta-blocker therapy on systolic and diastolic function in pulmonary arterial hypertension: A randomized controlled trial Source: International Congress 2014 – Pulmonary hypertension: improving treatment in PAH Year: 2014 REVEAL: a contemporary US pulmonary arterial hypertension registry Source: Eur Respir Rev 2012; 21: 8-18 Year: 2012 Macitentan for pulmonary arterial hypertension (PAH): Early clinical experience of 94 patients Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 “Rehab for all!” Is it too early in pulmonary arterial hypertension? Source: Eur Respir J, 54 (5) 1901558; 10.1183/13993003.01558-2019 Year: 2019 Clinical trial design and new therapies for pulmonary arterial hypertension Source: Eur Respir J, 53 (1) 1801908; 10.1183/13993003.01908-2018 Year: 2019 Image-based recommendations for the evaluation of pulmonary embolism and arterial hypertension: what? when? how? Source: Virtual Congress 2020 – Image-based guidelines and recommendations in respiratory diseases Year: 2020 Pulmonary arterial hypertension: treatment options Source: International Congress 2018 – ME10 Pulmonary arterial hypertension: treatment options FULLY BOOKED Year: 2018 Combination therapy for pulmonary arterial hypertension: still more questions than answers Source: Eur Respir J 2004; 24: 339-340 Year: 2004 Hemodynamic and clinical relevance of “borderline pulmonary hypertension“ Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I Year: 2013 Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience Source: Eur Respir Rev 2017; 26: 160055 Year: 2017 Learning from registries in pulmonary arterial hypertension: pitfalls and recommendations Source: Eur Respir Rev, 28 (154) 190050; 10.1183/16000617.0050-2019 Year: 2019